CVM: CRO Selected for Registrational Trial

Zacks Small Cap Research12-09

By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) has made progress advancing the prerequisites for the upcoming registrational trial, selecting the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490502776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-09 17:39","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490502776","market":"us","top_or_hot":-1,"title":"CVM: CRO Selected for Registrational Trial","media":"Zacks Small Cap Research","content":"<div>\n<p>By John Vandermosten, CFA\n NYSE:CVM\nREAD THE FULL CVM RESEARCH REPORT\nCEL-SCI Corporation (NYSE:CVM) has made progress advancing the prerequisites for the upcoming registrational trial, selecting the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cvm-cro-selected-registrational-trial-093900095.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVM: CRO Selected for Registrational Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVM: CRO Selected for Registrational Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 17:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cvm-cro-selected-registrational-trial-093900095.html><strong>Zacks Small Cap Research</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By John Vandermosten, CFA\n NYSE:CVM\nREAD THE FULL CVM RESEARCH REPORT\nCEL-SCI Corporation (NYSE:CVM) has made progress advancing the prerequisites for the upcoming registrational trial, selecting the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cvm-cro-selected-registrational-trial-093900095.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OS","symbol_name":"Onestream Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/cvm-cro-selected-registrational-trial-093900095.html","article_id":"2490502776","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490502776","pubTimestamp":1733737140,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"CEL-SCI Corporation  has made progress advancing the prerequisites for the upcoming registrational trial, selecting the contract research organization  that will run it and coming to an agreement with the FDA on which biomarkers are appropriate for selecting patients. The view of oncologists as expressed by the FDA’s ODAC is that using checkpoint inhibitors to treat low PD-L1 expressing patients provides limited efficacy and could even be harmful. This view opens the door for the use of Multikine, if approved, in the low expressing PD-L1 patient population based on its efficacy in this group.FDA ODAC opines against use of checkpoints in low PD-L1 expression patients – October 2024. FDA agrees to use of PD-L1 biomarker in Multikine registration study – November 2024. The 79 patients who were recommended to receive only radiotherapy benefited to an even greater degree from pre-surgery treatment with Multikine compared to the wider 114 patient group. This target low risk population  had a","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OS":"Onestream Inc","BK4192":"特殊消费者服务","CVM":"CEL-SCI Corp","BK4097":"系统软件","BK4139":"生物科技","PET":"Wag! Group Co"},"translate_title":"CVM：CRO入选注册试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVM":1,"OS":1,"PET":1},"content_text":"By John Vandermosten, CFA\n NYSE:CVM\nREAD THE FULL CVM RESEARCH REPORT\nCEL-SCI Corporation (NYSE:CVM) has made progress advancing the prerequisites for the upcoming registrational trial, selecting the contract research organization (CRO) that will run it and coming to an agreement with the FDA on which biomarkers are appropriate for selecting patients. The view of oncologists as expressed by the FDA’s ODAC is that using checkpoint inhibitors to treat low PD-L1 expressing patients provides limited efficacy and could even be harmful. This view opens the door for the use of Multikine, if approved, in the low expressing PD-L1 patient population based on its efficacy in this group.\nCEL-SCI Milestones\n\nGiovanni Selvaggi joins CEL-SCI as clinical advisor – June 2024\nPresentation at the International Drug Discovery Science & Technology (IDDST) Congress – June 2024\nCEL-SCI appoints Robert Watson as Chairperson of the Board – July 2024\nFeedback from various regulatory agencies - 2024\nSubmission of license application to various agencies – 2024+\nGrant of pediatric waiver by UK’s MHRA – September 2024\nESMO poster presentation provides new data – September 2024\nUK’s MHRA grants pediatric waiver to Multikine – September 2024\nErgomed selected as CRO for confirmatory trial – October 2024\nFDA ODAC opines against use of checkpoints in low PD-L1 expression patients – October 2024\nFDA agrees to use of PD-L1 biomarker in Multikine registration study – November 2024\n\nESMO Poster Presentation\nOn September 16th, 2024, Dr. József Tímár, presented a poster entitled “Prognostic significance of diagnostic staging in treatment naïve, resectable locally advanced primary oral cavity squamous cell carcinoma for neoadjuvant Leukocyte Interleukin Injection immunotherapy.” He presented at the European Society for Medical Oncology (ESMO) 2024 Congress which was held in Barcelona, Spain. The poster presented graphical data comparing high risk and low risk subjects who were evaluated in the IT-MATTERS trial measuring the probability of overall survival (OS) over time. The subpopulation included in the data set consisted of 114 subjects who met the target population selection criteria. The high-risk group included patients that presented a high risk of cancer recurrence and who were recommended to undergo chemotherapy following surgery (N=35). The low risk group included patients that were recommended to be given radiotherapy but not chemotherapy after surgery (N=79). Both groups showed a survival benefit for the Multikine arm. \nThe 79 patients who were recommended to receive only radiotherapy benefited to an even greater degree from pre-surgery treatment with Multikine compared to the wider 114 patient group. This target low risk population (n=38) had a 5-year overall survival of 82.6% when treated with Multikine vs. 47.3% when treated with standard of care alone (n=41), without overlap in their respective 95% confidence intervals. More recent analysis for the target low risk population (n=79) produced a hazard ratio of 0.27 (95% CI [0.12, 0.64], Wald p=0.0027) achieving a 73% reduction in overall risk of death.\nWhile the overall survival benefit was clear and statistically significant (log rank p=0.0015) for the entire target population (n=114), the 79 patients who were recommended to receive only radiotherapy benefited to an even greater degree from pre-surgery treatment with Multikine than the group of 114 as a whole. This target low risk population (n=38) had a 5-year overall survival of 82.6% when treated with Multikine vs. 47.3% when treated with standard of care alone (n=41), without overlap in their respective 95% confidence intervals. More recent analysis for the target low risk population (n=79) showed a hazard ratio of 0.27 (95% CI [0.12, 0.64], Wald p=0.0027) achieving a 73% reduction in overall risk of death.\nLooking ahead, CEL-SCI management postulated that the use of advanced imaging techniques such as positron emission tomography (PET) may help further improve patient selection and generate a higher success rate for Multikine. PET scans will be used in the upcoming confirmatory registration study for FDA approval.\nClinical Research Organization (CRO) Selection \nCEL-SCI selects Ergomed to serve as its CRO for the upcoming confirmatory registration study of Multikine. Details of the selection were included in an October 1st press release. Ergomed had previously provided CRO services to CEL-SCI for the management of the IT-MATTERS trial. Ergomed will manage the trial globally at multiple sites. The announcement reminded readers that the trial will be a 212-patient study enrolling newly-diagnosed, locally advanced, primary head and neck cancer. It will focus on patients with no lymph node involvement and low PD-L1 tumor expression. The anticipated start of the confirmatory trial is 1Q:25.\nFDA's Oncologic Drugs Advisory Committee (ODAC) Opinion\nThe FDA’s Oncologic Drugs Advisory Committee (ODAC) convened in September to evaluate the use of checkpoint inhibitors in different cancers and when certain therapies are appropriate depending on biomarker readings. The ODAC is a panel of expert advisors that provides recommendations to the FDA regarding cancer drugs and treat-ments. The committee consists of medical experts, oncologists, researchers, and other healthcare professionals specializing in cancer treatment whose primary role is to review and evaluate new cancer drugs, therapies, and treatments before they are approved for market use.\nThe ODAC provided an opinion on adequacy of PD-L1 expression as a predictive biomarker for patient selection in this patient population, risk-benefit assessments in different subpopulations defined by PD-L1 expression and ade-quacy of the cumulative data to restrict the approvals of immune checkpoint inhibitors based on PD-L1 expression. After reviewing the data, the ODAC voted 10-2 and 11-1 against the risk-benefit profile for PD-L1 inhibitors in various cancers in two separate votes. Committee members expressed concerns about the lack of benefit demonstrated for patients with low PD-L1 expression, while some members pointed to evidence that the use of the imm-une checkpoint inhibitors may add unnecessary toxicities for patients while also increasing financial burdens on patients. If our readers suffer from insomnia, a solution can be found in the near nine hour meeting on YouTube.\nThe ODAC’s view opens the door for products such as Multikine that work better in low expression PD-L1 tumors and could be a complement or alternative to checkpoint inhibitors for treatment of non-responsive patients.\nSUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. \n \nDISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490502776"}